Preventing NSAID toxicity to the upper gastrointestinal tract

  • James M. Scheiman

Opinion statement

  • Prevention of gastrointestinal toxicity begins with the selection of an appropriate analgesic or anti-inflammatory agent. For conditions without inflammation, such as some cases of osteoarthritis, an analgesic with no risk for gastrointestinal toxicity is appropriate.

  • Risk factors for nonsteroidal anti-inflammatory drug (NSAID)-related complications include advanced age; history of ulcer disease or gastrointestinal bleeding; concomitant corticosteroid or anticoagulant use; use of high-dose or multiple NSAIDs; and certain chronic diseases, such as cardiovascular disease. If an NSAID must be used in a patient with risk factors, the patient should receive the lowest-risk NSAID and, in most cases, co-therapy to reduce the risk for NSAID-associated ulcers and their complications.

  • The PGE1 prostaglandin analogue misoprostol is highly efficacious for the prevention of both gastric and duodenal ulcers and has also been shown to reduce the incidence of NSAID-induced ulcer complications. Side effects, such as diarrhea, may limit patient acceptance of the drug.

  • Acid suppression with traditional ulcer-healing doses of H2-blockers significantly reduces rates of duodenal ulcer but is ineffective in reducing gastric ulceration. More potent acid inhibition with double-dose H2-blockers reduces rates of both gastric and duodenal ulcers.

  • Proton-pump inhibitors, such as omeprazole, have been shown to prevent gastric and duodenal ulcers with an efficacy equal to that of misoprostol. They also reduce NSAID-related dyspepsia.

  • Specific cyclooxygenase-2 (COX-2) inhibitors are associated with a markedly reduced rate of endoscopic ulcers. Very high-risk patients who receive these agents may still require co-therapy to prevent complications or reduce dyspepsia. This protocol may be changed by the results of long-term gastrointestinal outcome studies now underway.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Stat Bull Metrop Insur Co. Antiarthritis medication usage, United States, 1991. 1992, 73:25–34.Google Scholar
  2. 2.
    Singh G, Ramey DR: NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol 1998, 25:16.Google Scholar
  3. 3.
    Goldstein JL: Public misunderstanding of nonsteroidal antiinflammatory drug (NSAID)-mediated gastrointestinal complications toxicity: a serious potential health threat. Gastroenterology 1998, 114:G0555.Google Scholar
  4. 4.
    Scheiman JM: NSAIDs, cytoprotection, and gastrointestinal injury. Gastroenterol Clin North Am 1996, 25:279–298.PubMedCrossRefGoogle Scholar
  5. 5.
    Vane JR, Mitchell JA, Appelton I, et al.: Inducible isoforms of cyclooxygenase and nitric acid synthase in inflammation. Proc Natl Acad Sci U S A 1994, 91:2046–2050.PubMedCrossRefGoogle Scholar
  6. 6.
    Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 1998, 104:413–421. This paper highlights the difficulties in characterizing NSAIDs selectively for COX isoenzymes.PubMedCrossRefGoogle Scholar
  7. 7.
    Scheiman JM, Elta GH: Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans. Semin Arthritis Rheum 1990, 20:121–127.PubMedCrossRefGoogle Scholar
  8. 8.
    Roth SH, Tindall EA, Jain AD, et al.: A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal mucosa. Arch Intern Med 1993, 153:2565–2571.PubMedCrossRefGoogle Scholar
  9. 9.
    Laine L, Sloane R, Ferretti M, Cominelli F: A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995, 42:428–433.PubMedCrossRefGoogle Scholar
  10. 10.
    Slattery J, Warlow CP, Shorrock CJ, Langman MJS: Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995, 37:509–511.PubMedGoogle Scholar
  11. 11.
    Kurata JH, Abbey DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990, 12:260–266.PubMedCrossRefGoogle Scholar
  12. 12.
    Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310:827–830.PubMedGoogle Scholar
  13. 13.
    Cryer B, Luk G, Feldman M: Effects of very low doses of aspirin (ASA) on gastric duodenal and rectal prostaglandins (PG2) and mucosal injury. Gastroenterology 1995, 108:A77.CrossRefGoogle Scholar
  14. 14.
    Silverstein F, Graham D, Senior J, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241–249.PubMedGoogle Scholar
  15. 15.
    Henry D, Lim L, Garcia Rodriguez L, et al.: Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. BMJ 1996, 312:1563–1566. This provides an important synthesis of data on the relative ulcerogenicity of various NSAIDs.PubMedGoogle Scholar
  16. 16.
    Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28:527–532.PubMedGoogle Scholar
  17. 17.
    Hawkey CJ, Langstrom G, Naesdal J, Yeomans N: Significance of symptoms during healing and maintenance of NSAID-associated gastroduodenal lesions with omeprazole, misoprostol, and ranitidine. Gastroenterology 1997, 112:A144.CrossRefGoogle Scholar
  18. 18.
    Roth SH: Efficacy of antacid therapy for NSAIDinduced symptomatic gastropathy. Am J Gastroenterol 1993, 88:1516.Google Scholar
  19. 19.
    Bijlsma JW: Treatment of endoscopy-negative NSAIDinduced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988, 2(suppl 2):75–84.PubMedGoogle Scholar
  20. 20.
    Ekstrom P, Carling L, Wetterhus S, et al.: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996, 31:753–758.PubMedGoogle Scholar
  21. 21.
    Graham D, Agrawal N, Roth S: Prevention of NSAIDinduced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988, 2:1277–1280.PubMedCrossRefGoogle Scholar
  22. 22.
    Raskin JB, White R, Jaszewski R, et al.: Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double blind, multicenter study. Am J Gastroenterol 1996, 91:223–227.PubMedGoogle Scholar
  23. 23.
    Raskin JB, White RH, Jackson JE: Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995, 123:344–350.PubMedGoogle Scholar
  24. 24.
    Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996, 334:1435–1439.PubMedCrossRefGoogle Scholar
  25. 25.
    Cullen D, Bardhan KD, Eisner M, et al.: Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Aliment Pharmacol Ther 1998, 12:135–140.PubMedCrossRefGoogle Scholar
  26. 26.
    Yeomans ND, Zsolt T, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:719–726.PubMedCrossRefGoogle Scholar
  27. 27.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:727–734. This paper supports the use of proton-pump inhibitors as an alternative to misoprostol for NSAID prophylaxis.PubMedCrossRefGoogle Scholar
  28. 28.
    Kurumbail RG, Stevens AM, Gierse JK, et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644–648.PubMedCrossRefGoogle Scholar
  29. 29.
    Hawkey CJ: COX-2 inhibitors. Lancet 1999, 353:307–314. This is a timely, comprehensive review.PubMedCrossRefGoogle Scholar
  30. 30.
    Hawkey C, Laine L, Simon T, et al.: A comparison of the effect of rofecoxib (a COX-2 specific inhibitor), ibuprofen, or placebo on the gastroduodenal mucosa of osteoarthritics. In press.Google Scholar
  31. 31.
    Scheiman JM: Commentary on “Meta analysis: Misoprostol reduced NSAID-induced gastrointestinal injury.” ACP J Club 1997, 124:34.Google Scholar
  32. 32.
    Simon LS, Hatoum HT, Bittman RM, et al.: Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA Trial. Fam Med 1996, 28:204–210.PubMedGoogle Scholar
  33. 33.
    Quang-Hiang J, Hunt R: Gastrointestinal complications associated with nabumetone. Am J Med 1999, In press.Google Scholar
  34. 34.
    Fendrick AM, Bandekar R, Chernew ME, Scheiman JM: Impact of NSAID choice and patient symptoms on the cost-effectiveness of strategies to prevent NSAID gastropathy. Gastroenterology 1998, 114:A120.CrossRefGoogle Scholar
  35. 35.
    Schoenfeld P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999, In press.Google Scholar
  36. 36.
    Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995, 109:524–533.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • James M. Scheiman
    • 1
  1. 1.Division of GastroenterologyUniversity of Michigan Medical CenterAnn Arbor

Personalised recommendations